ORBIMED ADVISORS LLC's Net Worth

$524 Million

Who is ORBIMED ADVISORS LLC?

ORBIMED ADVISORS LLC has an estimated net worth of $524 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., COMPLETE GENOMICS INC, INSULET CORP, Volcano Corp, AMARIN CORP PLC\UK, Relypsa Inc, ChemoCentryx, Inc., Mirati Therapeutics, Inc., GLAUKOS Corp, INTERCEPT PHARMACEUTICALS INC, Intellia Therapeutics, Inc., ALPINE IMMUNE SCIENCES, INC., SUPERNUS PHARMACEUTICALS INC, PIERIS PHARMACEUTICALS, INC., ViewRay, Inc., CTI BIOPHARMA CORP, Aerpio Pharmaceuticals, Inc., Sierra Oncology, Inc., Adaptimmune Therapeutics PLC, Pacira Pharmaceuticals, Inc., Loxo Oncology, Inc., Sientra, Inc., SELECTA BIOSCIENCES INC, Nabriva Therapeutics AG, Xtant Medical Holdings, Inc., Dimension Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Kala Pharmaceuticals, Inc., scPharmaceuticals Inc., SteadyMed Ltd., SYNLOGIC, INC., OTONOMY, INC., Arsanis, Inc., RESPONSE BIOMEDICAL CORP, AVANIR PHARMACEUTICALS, Roka BioScience, Inc., Audentes Therapeutics, Inc., Biodel Inc, AMBIT BIOSCIENCES CORP, Anthera Pharmaceuticals Inc, NxStage Medical, Inc., ACCELERON PHARMA INC, MEMORY PHARMACEUTICALS CORP, ORPHAN MEDICAL INC, Kun Run Biotechnology, Inc., ARYx Therapeutics, Inc., CRYOCOR INC, AEROGEN INC, BTHC VI Inc, Corvus Pharmaceuticals, Inc., GIVEN IMAGING LTD, LIFECELL CORP, DOV PHARMACEUTICAL INC, resTORbio, Inc., ArriVent Biopharma, Inc., AVEDRO INC, Turning Point Therapeutics, Inc., Keros Therapeutics, Inc., Guardant Health, Inc., CONSTELLATION PHARMACEUTICALS INC, PMV Pharmaceuticals, Inc., Prelude Therapeutics Inc, Crinetics Pharmaceuticals, Inc., Verona Pharma plc, Fusion Pharmaceuticals Inc., SI-BONE, Inc., Inspire Medical Systems, Inc., Repare Therapeutics Inc., Arcutis Biotherapeutics, Inc., Theseus Pharmaceuticals, Inc., Alector, Inc., Janux Therapeutics, Inc., NeuroPace Inc, Edgewise Therapeutics, Inc., Tricida, Inc., Kinnate Biopharma Inc., SpringWorks Therapeutics, Inc., Ikena Oncology, Inc., ARVINAS INC., ARMO BioSciences, Inc., Prevail Therapeutics Inc., Synthorx, Inc., ARS Pharmaceuticals, Inc., Disc Medicine, Inc., GRAYBUG VISION, INC., Acutus Medical, Inc., LogicBio Therapeutics, Inc., 89bio, Inc., Terns Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc., Galecto, Inc., Decibel Therapeutics, Inc., Compass Therapeutics, Inc., Passage BIO, Inc., Principia Biopharma Inc., TELA Bio, Inc., NextCure, Inc., Enliven Therapeutics, Inc., Third Harmonic Bio, Inc., Pandion Therapeutics Holdco LLC, ORTHOVITA INC, Turnstone Biologics Corp., Homology Medicines, Inc., and Traws Pharma, Inc..

SEC CIK

ORBIMED ADVISORS LLC's CIK is 0001055951

Past Insider Trading and Trends

2019 was ORBIMED ADVISORS LLC's most active year for acquiring shares with 4 total transactions. ORBIMED ADVISORS LLC's most active month to acquire stocks was the month of October. 2019 was ORBIMED ADVISORS LLC's most active year for disposing of shares, totalling 3 transactions. ORBIMED ADVISORS LLC's most active month to dispose stocks was the month of October. 2020 saw ORBIMED ADVISORS LLC paying a total of $7,275,660.00 for 1,455,132 shares, this is the most they've acquired in one year. In 2023 ORBIMED ADVISORS LLC cashed out on 3,448 shares for a total of $102,129.76, their largest year based on trade value.